The 10-second takeaway
For the quarter ended Oct. 31 (Q4), Bio-Reference Laboratories met expectations on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded significantly and GAAP earnings per share expanded significantly.
Gross margins contracted, operating margins expanded, net margins increased.
Bio-Reference Laboratories logged revenue of $176.1 million. The five analysts polled by S&P Capital IQ predicted net sales of $175.3 million on the same basis. GAAP reported sales were 16% higher than the prior-year quarter's $151.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.46. The five earnings estimates compiled by S&P Capital IQ forecast $0.46 per share. GAAP EPS of $0.46 for Q4 were 24% higher than the prior-year quarter's $0.37 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 49.6%, 190 basis points worse than the prior-year quarter. Operating margin was 13.3%, 480 basis points better than the prior-year quarter. Net margin was 7.3%, 40 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $172.6 million. On the bottom line, the average EPS estimate is $0.31.
Next year's average estimate for revenue is $757.9 million. The average EPS estimate is $1.77.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 321 members out of 339 rating the stock outperform, and 18 members rating it underperform. Among 102 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 99 give Bio-Reference Laboratories a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Bio-Reference Laboratories is buy, with an average price target of $31.80.
Is Bio-Reference Laboratories the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Bio-Reference Laboratories to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool owns shares of Bio-Reference Laboratories. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.